Indaptus Therapeutics Appoints New CFO and Director Following Recent Change of Control

summarizeSummary

Indaptus Therapeutics announced a significant leadership transition, appointing a new Chief Financial Officer and an independent director, following a recent change of control and rescue financing.

check_boxKey Events

• CFO Resignation

  Nir Sassi resigned as Chief Financial Officer on April 1, 2026. The company stated his resignation was not based on any disagreement with operations, policies, or practices.

• New CFO Appointed

  Yu Ding was appointed Chief Financial Officer, effective April 1, 2026. Mr. Ding brings over 20 years of financial executive experience, including roles at publicly traded companies on the Shanghai and Hong Kong Stock Exchanges.

• New Independent Director Appointed

  Qinglai Lu was appointed to the Board of Directors, effective April 8, 2026, and is deemed independent. Mr. Lu has over 20 years of experience in corporate finance, banking, and asset management in the Asia-Pacific region.

• Audit Committee Changes

  Matthew McMurdo resigned from the Audit Committee, while newly appointed director Qinglai Lu and Jerome Jabbour were appointed to the committee.

auto_awesomeAnalysis

This 8-K details significant leadership changes at Indaptus Therapeutics, including the resignation of its CFO and the appointment of a new Chief Financial Officer and an independent director. These changes occur immediately following a major change of control and a highly dilutive 'rescue' financing, as disclosed in recent filings on March 24th and 31st. The new CFO, Yu Ding, and new director, Qinglai Lu, bring extensive financial and capital markets experience, particularly in the Asia-Pacific region, aligning with the new investor group. This management overhaul is a critical step for the company as it navigates a distressed financial situation, marked by a going concern warning and halted clinical programs, and attempts to establish a new strategic direction under its new ownership. The stock is currently trading near its 52-week low, underscoring the urgency and importance of these leadership transitions.